Clinical Trial Update: Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating Vopratelimab in combination with a CTLA-4 inhibitor in patients previously treated with PD-1/PD-L1 inhibitors (NSCLC or urothelial cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Urothelial Cancer

Drugs mentioned

• Vopratelimab (vopratelimab)

Snippet

Sponsor: Jounce Therapeutics, Inc. | Conditions: Cancer | Phase 2 | Status: COMPLETED